# Evaxion A/S

Type: Company (EVAX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/evaxion-as
Canonical HTML page: https://getbiobrief.com/entity/evaxion-as

## Timeline

- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2025-09**: Merck exercises EVX-B3 option — Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.

## Recent coverage (1 stories)

### Merck's EVX-B3 Option Turns 1.2M Evaxion Stake Into Validation
2026-08-22 13:50:28 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's option to in-license Evaxion's EVX-B3 vaccine candidate, combined with a 1.21 million-share stake, provides early validation for the biotech's AI antigen discovery platform. For biotech investors, the deal is a discovery-stage bet with long clinical timelines.
Full story: https://getbiobrief.com/story/merck-evaxion-evb3-ai-vaccine-validation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.